Login / Signup

Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.

Willem CollierLesley A InkerBenjamin HaalandGerald B AppelSunil V BadveFernando Caravaca-FontánJohn ChalmersJürgen FloegeMarian GoicoecheaEnyu ImaiTazeen H JafarJulia B LewisPhilip Kam-Tao LiFrancesco LocatelliBart D MaesBrendon L NeuenVicente E TorresGiuseppe RemuzziFrancesco P SchenaChristoph WannerHiddo J Lambers HeerspinkTom Greenenull null
Published in: Clinical journal of the American Society of Nephrology : CJASN (2023)
These analyses indicate consistency of the performance of total slope over 3 years, which provides further evidence for its validity as a surrogate end point in RCTs representing varied CKD populations.
Keyphrases
  • chronic kidney disease
  • clinical trial
  • phase ii